Payment overview · 2025
General Payments
$769.60
36 reported records · 16 companies
Healthcare provider profile · identity verified
Charles Patrick Coyne, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · WARRENTON, MO · NPI 1295048031
Verified facts
What the public records show
CMS Open Payments records show Charles Patrick Coyne, M.D. received $769.60 in general payments during 2025 across 36 reported records.
AstraZeneca Pharmaceuticals LP accounted for 36.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 27 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Jardiance, Mounjaro, Ozempic.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 31 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Symbicort by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 148 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 148 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 37 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 34 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 134 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 121 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $276.86 | 36.0% | 9 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $97.54 | 12.7% | 5 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $66.92 | 8.7% | 4 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $47.75 | 6.2% | 2 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $36.82 | 4.8% | 2 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $35.94 | 4.7% | 2 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $34.28 | 4.5% | 2 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $31.59 | 4.1% | 2 | 2025 |
| Organon LLC | Unresolved — no canonical attribution shown | $24.61 | 3.2% | 1 | 2025 |
| Xeris Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $20.84 | 2.7% | 1 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $18.30 | 2.4% | 1 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $17.79 | 2.3% | 1 | 2025 |
| Teva Pharmaceuticals USA, Inc. | Unresolved — no canonical attribution shown | $16.16 | 2.1% | 1 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $15.62 | 2.0% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $14.52 | 1.9% | 1 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $14.06 | 1.8% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $769.60 | 36 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $221.19 | 6 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $176.70 | 3 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $54.04 | 3 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $53.19 | 3 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $43.50 | 2 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $43.50 | 2 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $37.12 | 2 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $35.94 | 2 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $34.28 | 2 | 2025 |
Source payment records
|
|||||
| NEXPLANON Normalized: nexplanon |
Drug | Organon LLC | $24.61 | 1 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $22.16 | 1 | 2025 |
Source payment records
|
|||||
| PROLIA Normalized: prolia |
Biological | Amgen Inc. | $22.16 | 1 | 2025 |
Source payment records
|
|||||
| GVOKE HYPOPEN Normalized: gvoke hypopen |
Drug | Xeris Pharmaceuticals, Inc. | $20.84 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $19.38 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $19.38 | 1 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $18.30 | 1 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $17.79 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $16.72 | 1 | 2025 |
Source payment records
|
|||||
| AUSTEDO XR Normalized: austedo xr |
Drug | Teva Pharmaceuticals USA, Inc. | $16.16 | 1 | 2025 |
Source payment records
|
|||||
| PAXLOVID Normalized: paxlovid |
Drug | PFIZER INC. | $16.07 | 1 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $15.62 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $14.87 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $14.66 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $14.66 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $14.52 | 1 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $14.06 | 1 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $13.73 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 121 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 148 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 37 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 134 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
31 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
148 | 37 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
148 | 37 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
37 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
34 | 13 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
134 | 33 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
121 | 28 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 601 | 185 |
| Lisinopril | Lisinopril | 446 | 138 |
| Amlodipine Besylate | Amlodipine Besylate | 365 | 111 |
| Levothyroxine Sodium | Levothyroxine Sodium | 354 | 106 |
| Tramadol Hcl | Tramadol Hcl | 323 | 84 |
| Alprazolam | Alprazolam | 310 | 71 |
| Pantoprazole Sodium | Pantoprazole Sodium | 292 | 79 |
| Omeprazole | Omeprazole | 265 | 88 |
| Zolpidem Tartrate | Zolpidem Tartrate | 265 | 57 |
| Gabapentin | Gabapentin | 261 | 74 |
| Trazodone Hcl | Trazodone Hcl | 227 | 71 |
| Losartan Potassium | Losartan Potassium | 214 | 64 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 200 | 64 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 200 | 69 |
| Sertraline Hcl | Sertraline Hcl | 185 | 42 |
| Metformin Hcl | Metformin Hcl | 168 | 58 |
| Tizanidine Hcl | Tizanidine Hcl | 165 | 59 |
| Furosemide | Furosemide | 158 | 47 |
| Tamsulosin Hcl | Tamsulosin Hcl | 155 | 48 |
| Meloxicam | Meloxicam | 153 | 52 |
| Jardiance | Empagliflozin | 148 | 37 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 145 | 38 |
| Metoprolol Succinate | Metoprolol Succinate | 139 | 49 |
| Hydrochlorothiazide | Hydrochlorothiazide | 137 | 47 |
| Pregabalin | Pregabalin | 137 | 27 |
| Ozempic | Semaglutide | 134 | 33 |
| Eliquis | Apixaban | 121 | 28 |
| Bupropion Xl | Bupropion Hcl | 118 | 31 |
| Metformin Hcl Er | Metformin Hcl | 116 | 38 |
| Clopidogrel | Clopidogrel Bisulfate | 112 | 23 |
| Buspirone Hcl | Buspirone Hcl | 111 | 24 |
| Metoprolol Tartrate | Metoprolol Tartrate | 108 | 29 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 107 | 34 |
| Lorazepam | Lorazepam | 99 | 23 |
| Simvastatin | Simvastatin | 99 | 31 |
| Fluticasone Propionate | Fluticasone Propionate | 97 | 37 |
| Montelukast Sodium | Montelukast Sodium | 94 | 31 |
| Pravastatin Sodium | Pravastatin Sodium | 88 | 30 |
| Carvedilol | Carvedilol | 86 | 28 |
| Finasteride | Finasteride | 85 | 28 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 84 | 18 |
| Duloxetine Hcl | Duloxetine Hcl | 77 | 19 |
| Allopurinol | Allopurinol | 73 | 21 |
| Quetiapine Fumarate | Quetiapine Fumarate | 70 | 12 |
| Glimepiride | Glimepiride | 67 | 24 |
| Ondansetron Odt | Ondansetron | 65 | 17 |
| Famotidine | Famotidine | 64 | suppressed |
| Myrbetriq | Mirabegron | 63 | 17 |
| Warfarin Sodium | Warfarin Sodium | 63 | 12 |
| Escitalopram Oxalate | Escitalopram Oxalate | 62 | 17 |
| Alendronate Sodium | Alendronate Sodium | 60 | 12 |
| Ropinirole Hcl | Ropinirole Hcl | 59 | 15 |
| Dicyclomine Hcl | Dicyclomine Hcl | 57 | 13 |
| Diazepam | Diazepam | 55 | 13 |
| Glipizide Er | Glipizide | 55 | 16 |
| Clonazepam | Clonazepam | 53 | 15 |
| Fluoxetine Hcl | Fluoxetine Hcl | 49 | 16 |
| Glipizide | Glipizide | 47 | 16 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 46 | 24 |
| Ibuprofen | Ibuprofen | 46 | 13 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 45 | 18 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 45 | 13 |
| Citalopram Hbr | Citalopram Hydrobromide | 43 | 13 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 43 | 15 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 42 | 16 |
| Celecoxib | Celecoxib | 42 | suppressed |
| Ezetimibe | Ezetimibe | 40 | 16 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 40 | 11 |
| Potassium Chloride | Potassium Chloride | 39 | 12 |
| Donepezil Hcl | Donepezil Hcl | 38 | 13 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 38 | 11 |
| Mounjaro | Tirzepatide | 37 | suppressed |
| Atenolol | Atenolol | 36 | 13 |
| Diclofenac Sodium | Diclofenac Sodium | 36 | 12 |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 35 | suppressed |
| Zolpidem Tartrate Er | Zolpidem Tartrate | 35 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 34 | suppressed |
| Trulicity | Dulaglutide | 34 | 13 |
| Midodrine Hcl | Midodrine Hcl | 33 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 33 | 23 |
| Farxiga | Dapagliflozin Propanediol | 31 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 31 | suppressed |
| Spironolactone | Spironolactone | 31 | 13 |
| Methocarbamol | Methocarbamol | 30 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 30 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 29 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 29 | 29 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 29 | suppressed |
| Levetiracetam | Levetiracetam | 29 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 29 | suppressed |
| Azithromycin | Azithromycin | 28 | 27 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 28 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 27 | 24 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 27 | suppressed |
| Topiramate | Topiramate | 26 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 26 | suppressed |
| Lamotrigine | Lamotrigine | 25 | suppressed |
| Lovastatin | Lovastatin | 25 | suppressed |
| Methylprednisolone | Methylprednisolone | 25 | 19 |
| Breo Ellipta | Fluticasone/Vilanterol | 24 | suppressed |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 23 | 23 |
| Hydralazine Hcl | Hydralazine Hcl | 23 | 12 |
| Memantine Hcl | Memantine Hcl | 23 | suppressed |
| Breyna | Budesonide/Formoterol Fumarate | 22 | suppressed |
| Mirtazapine | Mirtazapine | 22 | suppressed |
| Prednisone | Prednisone | 22 | 19 |
| Propranolol Hcl Er | Propranolol Hcl | 22 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 22 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 22 | suppressed |
| Ketoconazole | Ketoconazole | 21 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 21 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 21 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 20 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 20 | suppressed |
| Eszopiclone | Eszopiclone | 19 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 19 | 13 |
| Levemir Flexpen | Insulin Detemir | 19 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 19 | suppressed |
| Mupirocin | Mupirocin | 19 | 13 |
| Nebivolol Hcl | Nebivolol Hcl | 19 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 18 | 17 |
| Januvia | Sitagliptin Phosphate | 18 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 17 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 17 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 17 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 17 | suppressed |
| Colchicine | Colchicine | 16 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 16 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 16 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 16 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 16 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 15 | suppressed |
| Brilinta | Ticagrelor | 15 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 15 | suppressed |
| Valsartan | Valsartan | 15 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 14 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 14 | suppressed |
| Estradiol | Estradiol | 14 | suppressed |
| Lactulose | Lactulose | 14 | suppressed |
| Nifedipine Er | Nifedipine | 14 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 14 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 14 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 13 | suppressed |
| Belsomra | Suvorexant | 13 | suppressed |
| Metronidazole | Metronidazole | 13 | 11 |
| Nitroglycerin | Nitroglycerin | 13 | suppressed |
| Nystatin | Nystatin | 13 | 12 |
| Temazepam | Temazepam | 13 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 13 | suppressed |
| Lithium Carbonate | Lithium Carbonate | 12 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 12 | 12 |
| Sumatriptan Succinate | Sumatriptan Succinate | 12 | suppressed |
| Xarelto | Rivaroxaban | 12 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 11 | suppressed |
| Biktarvy | Bictegrav/Emtricit/Tenofov Ala | 11 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 11 | suppressed |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 11 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 11 | suppressed |
| Fluconazole | Fluconazole | 11 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 11 | suppressed |
| Prenatal Vitamin Plus Low Iron | Pnv,calcium 72/Iron/Folic Acid | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $769.60 · 36 records | AstraZeneca Pharmaceuticals LP | AIRSUPRA, AUSTEDO XR, BREZTRI, Cologuard Collection Kit, ELIQUIS, EVENITY, GEMTESA, GVOKE HYPOPEN, JARDIANCE, Korlym, MOUNJARO, NEXPLANON, NURTEC ODT, OTEZLA, Ozempic, PAXLOVID, PROLIA, QULIPTA, REPATHA, REXULTI, UBRELVY, VOQUEZNA, VRAYLAR, Wegovy, XIFAXAN, ZAVZPRET, ZEPBOUND | 9 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error